Disease · MONDO_0012819
diabetic ketoacidosis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. diabetic ketoacidosis. Diseases, record MONDO_0012819. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0012819
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| INSULIN GLARGINE | CHEMBL1201497 | Protein | Phase 2 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| ANAKINRA | CHEMBL1201570 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| THIAMINE | CHEMBL1588 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INSULIN DEGLUDEC | CHEMBL2107869 | Protein | Phase 1/2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ARGININE HYDROCHLORIDE | CHEMBL1200381 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SEMAGLUTIDE | CHEMBL2108724 | Protein | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EMPAGLIFLOZIN | CHEMBL2107830 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INSULIN HUMAN | CHEMBL1201631 | Protein | Unknown | ClinicalTrials.gov | 7 | 7 | 6 | Drugs and targets |
| INSULIN ASPART | CHEMBL1201496 | Protein | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets6
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| INSR | Insulin receptor | 4 | Insulin receptor agonist | Phase 2 | https://conductscience.org/library/genes/3643 | Drugs and targets |
| DPP4 | Dipeptidyl peptidase 4 | 1 | Dipeptidyl peptidase IV inhibitor | Unknown | https://conductscience.org/library/genes/1803 | Drugs and targets |
| GLP1R | Glucagon-like peptide 1 receptor | 1 | Glucagon-like peptide 1 receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/2740 | Drugs and targets |
| IL1R1 | Interleukin-1 receptor type 1 | 1 | Interleukin-1 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/3554 | Drugs and targets |
| PPARG | Peroxisome proliferator-activated receptor gamma | 1 | Peroxisome proliferator-activated receptor gamma agonist | Unknown | https://conductscience.org/library/genes/5468 | Drugs and targets |
| SLC5A2 | Sodium/glucose cotransporter 2 | 1 | Sodium/glucose cotransporter 2 inhibitor | Phase 1 | https://conductscience.org/library/genes/6524 | Drugs and targets |
Trials20
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01365793 | Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis | Phase 3 | 1,389 | 2018-06-25 | Cerebral Edema, Diabetic Ketoacidosis | SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00179127 | Use of Insulin Glargine to Treat Diabetic Ketoacidosis | Not applicable | 75 | 2018-07-16 | Diabetic Ketoacidosis | INSULIN GLARGINE | Its record names the disease | ClinicalTrials.gov |
| NCT02006342 | Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis | Not applicable | 40 | 2017-05-16 | Diabetic Ketoacidosis | INSULIN GLARGINE, INSULIN HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT05752279 | Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis | Phase 3 | 547 | Diabetic Ketoacidosis | SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT05443802 | Comparison of a Low Dose to a Standard Dose of Insulin in Adult DKA in ICU to Reduce Metabolic Complications | Not applicable | 150 | Diabetic Ketoacidosis | INSULIN HUMAN | Its record names the disease | ClinicalTrials.gov | |
| NCT06057077 | Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus | Phase 1/2 | 120 | Type 1 Diabetes | INSULIN DEGLUDEC, SEMAGLUTIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT03717896 | Thiamine as Adjunctive Therapy for Diabetic Ketoacidosis | Phase 2 | 102 | Diabetic Ketoacidosis | THIAMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT07423559 | Relapse Among Diabetic Ketoacidosis Patients Maintained Basal Bolus Insulin Administration in Combination With Continuous Intravenous Insulin Infusion VS Non Maintaining Basal Insulin Patients | Not applicable | 100 | Diabetic Ketoacidosis, Insulin, Intensive Care Unit Stay | INSULIN HUMAN | Its record names the disease | ClinicalTrials.gov | |
| NCT05155917 | Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care | Phase 2 | 70 | Hyperglycaemic Crisis in Diabetes Mellitus, Diabetic Ketoacidosis, Hyperglycaemic Hyperosmolar Nonketotic Syndrome | INSULIN GLARGINE | Its record names the disease | ClinicalTrials.gov | |
| NCT07167693 | Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes | Phase 1/2 | 60 | Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic) | ARGININE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 20
See all 20 trialsComparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Insulin Glargine Plus Regular Insulin vs Control - Regular Insulin: Number of Participants Who Developed Hypoglycemia | 2 of 20 | 3 of 20 | 40 | NCT02006342 | Trial comparisons |
| Insulin Glargine Plus Regular Insulin vs Control - Regular Insulin: Number of Participants Admitted to the ICU | 6 of 20 | 4 of 20 | 40 | NCT02006342 | Trial comparisons |
| Insulin Glargine Plus Regular Insulin vs Control - Regular Insulin: serious adverse events | 0 of 20 | 0 of 20 | 40 | NCT02006342 | Trial comparisons |
Papers from its trials9
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0012819
GET https://conductscience.org/api/diseases/v1/MONDO_0012819/drugs